Study to Evaluate the Efficacy of Androxal in Controlling Blood Glucose in Men With Type-2 Diabetes Mellitus

A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 102 participants.

Also called NCT01191320

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 2
Enrolled
  • 102 participants (enrolled count) (from the registry)
Sponsor
Repros Therapeutics Inc. (from the registry)
Registry
  • NCT NCT01191320
Start date
(registry gives no type) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
United States (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT01191320. Randomized; quadruple masking; primary purpose treatment. Start 2010-10 (registry gives no type); primary completion 2011-12 (actual). Results posted on 2014-07-24.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Study to Evaluate the Efficacy of Androxal in Controlling Blood Glucose in Men With Type-2 Diabetes Mellitus
Condition
Type 2 Diabetes Mellitus
Condition
Secondary Hypogonadism
Intervention (Drug)
Placebo
Intervention (Drug)
Androxal
Lead sponsor
Repros Therapeutics Inc. (class: industry)

Record details

Record id
cardio:ct-nct01191320
Content hash
c4768b626e16e7ccdc4294c7b5592bfcc8a490a6b43b838b78226102b1975769